| Original language | English (US) |
|---|---|
| Pages (from-to) | 1092-1093 |
| Number of pages | 2 |
| Journal | Mayo Clinic proceedings |
| Volume | 96 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2021 |
ASJC Scopus subject areas
- Medicine(all)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Mayo Clinic proceedings, Vol. 96, No. 4, 04.2021, p. 1092-1093.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - In reply—Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research
AU - O'Horo, John C.
AU - Badley, Andrew D.
N1 - Funding Information: Potential Competing Interests: Dr O'Horo has been paid consulting fees by Elsevier and Bates College and small grants not directly pertaining to the presented work. Dr Badley is supported by grants from the National Institute of Allergy and Infectious Diseases (nos. AI110173 and AI120698), amfAR (#109593), and Mayo Clinic (HH Shieck Khalifa Bib Zayed Al-Nahyan Named Professorship of Infectious Diseases). He is a paid consultant for AbbVie, is a paid member of the data safety monitoring board for Corvus Pharmaceuticals, owns equity for scientific advisory work in Zentalis, and is founder and President of Splissen Therapeutics. Funding Information: Potential Competing Interests: Dr O’Horo has been paid consulting fees by Elsevier and Bates College and small grants not directly pertaining to the presented work. Dr Badley is supported by grants from the National Institute of Allergy and Infectious Diseases (nos. AI110173 and AI120698 ), amfAR (#109593), and Mayo Clinic (HH Shieck Khalifa Bib Zayed Al-Nahyan Named Professorship of Infectious Diseases). He is a paid consultant for AbbVie, is a paid member of the data safety monitoring board for Corvus Pharmaceuticals, owns equity for scientific advisory work in Zentalis, and is founder and President of Splissen Therapeutics.
PY - 2021/4
Y1 - 2021/4
UR - http://www.scopus.com/inward/record.url?scp=85103342336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103342336&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2021.02.005
DO - 10.1016/j.mayocp.2021.02.005
M3 - Letter
C2 - 33814077
AN - SCOPUS:85103342336
SN - 0025-6196
VL - 96
SP - 1092
EP - 1093
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 4
ER -